{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Epithelial+Ovarian+Cancer&page=16", "query": { "condition": "Metastatic Epithelial Ovarian Cancer", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 412, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Epithelial+Ovarian+Cancer&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Epithelial+Ovarian+Cancer&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T23:43:13.698Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03311334", "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Urothelial Carcinoma", "Primary Peritoneal Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Serous Epithelial Ovarian Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "DSP-7888 Dosing Emulsion", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-12-14", "completion_date": "2022-11-29", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311334" }, { "nct_id": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Cervical Cancer", "Non-small Cell Carcinoma", "Melanoma", "Ovarian Cancer", "Anogenital Cancers", "HPV - Anogenital Human Papilloma Virus Infection", "HPV-Related Cervical Carcinoma", "HPV-Related Carcinoma", "HPV-Related Squamous Cell Carcinoma", "HPV-Related Malignancy", "HPV-Related Adenocarcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Related Adenosquamous Carcinoma", "HPV-Associated Vaginal Adenocarcinoma", "HPV-Related Endocervical Adenocarcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Verrucous Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma", "HPV Positive Rectal Squamous Cell Carcinoma" ], "interventions": [ { "name": "TSC-204-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702 + TSC-202-A0201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-05-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973487" }, { "nct_id": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Esophageal Cancer", "Esophagogastric Junction (EGJ)", "Gastric (Stomach) Cancer", "Head and Neck Cancer", "Melanoma", "Ovarian Cancer", "Non-small Cell Lung (NSCLC)", "Urothelial Cancer" ], "interventions": [ { "name": "Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "USWM CT, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 120, "start_date": "2019-08-20", "completion_date": "2037-04-30", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 9, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044859" }, { "nct_id": "NCT02558348", "title": "Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Cervical Cancer" ], "interventions": [ { "name": "AL3818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2015-11", "completion_date": "2017-05-30", "has_results": false, "last_update_posted_date": "2019-06-19", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 2, "location_summary": "Chicago, Illinois • Salt Lake City, Utah", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02558348" }, { "nct_id": "NCT00089362", "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Gastric Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Melanoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Ovarian Epithelial Cancer", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Gastric Cancer", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Melanoma", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Melanoma", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Ovarian Epithelial Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "alvespimycin hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089362" }, { "nct_id": "NCT03861403", "title": "A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Advanced Triple Negative Breast Cancer", "Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer", "Advanced Metastatic Castration-Resistant Prostate Cancer", "Advanced Platinum-Resistant Ovarian Cancer" ], "interventions": [ { "name": "TRX518", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-05-20", "completion_date": "2020-07-14", "has_results": false, "last_update_posted_date": "2023-11-30", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 4, "location_summary": "Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861403" }, { "nct_id": "NCT05733000", "title": "CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Lung Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Urothelial Carcinoma", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Biliary Tract Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Lung Adenocarcinoma", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Biliary Tract Carcinoma", "Refractory Colorectal Carcinoma", "Refractory Gastroesophageal Junction Adenocarcinoma", "Refractory Lung Adenocarcinoma", "Refractory Ovarian Carcinoma", "Refractory Pancreatic Carcinoma", "Refractory Urothelial Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Devimistat", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2023-03-08", "completion_date": "2030-03-04", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733000" }, { "nct_id": "NCT06003231", "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Ovarian Neoplasms", "Endometrial Neoplasms", "Head and Neck Neoplasms" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2023-11-14", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 75, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06003231" }, { "nct_id": "NCT06395519", "title": "A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Breast Cancer", "Ovarian Cancer", "Prostate Cancer", "Epithelial Ovarian Cancer", "BRCA2 Mutation", "ER+ Breast Cancer", "Castrate Resistant Prostate Cancer", "BRCA1 Mutation", "BRCA Mutation", "Endometrial Cancer", "Colorectal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "ETX-19477", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "858 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-05-13", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 14, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06395519" }, { "nct_id": "NCT00010283", "title": "Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Graft Versus Host Disease", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "beclomethasone dipropionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "5 Years to 75 Years" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-14T23:43:13.698Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00010283" } ] }